Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

August 15, 2022 0

Gilead Sciences Good News for Breast Cancer Gilead Sciences' (GILD) product Trodelvy® has significantly improved the Overall …

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals’ Product AMX0035 for ALS

August 11, 2022 0

On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment Amylyx Pharmaceuticals (AMLX) …

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant Cancers

August 10, 2022 0

Hutchmed: Treating Advanced Refractory Metastatic Colorectal Cancer On August 8, 2022, Hutchmed (HCM) announced that pivotal global …

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

August 9, 2022 0

Reata Pharmaceuticals in the NEWS Reata Pharmaceuticals (RETA) on August 8, 2022, after the U.S. financial …

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

August 5, 2022 0

Gilead Sciences to Acquire MiroBio At $405 Million Gilead Sciences (GILD) and MiroBio - a privately …

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

August 3, 2022 0

Regenxbio in the NEWS Regenxbio (RGNX) announced, on August 3, 2022, its intention to file a …

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn’s Disease

July 29, 2022 0

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the …

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

July 26, 2022 0

Seagen, Astellas Pharma & Merck Collaboration Seagen (SGEN) and Astellas Pharma (ALPMY) have entered a clinical …

Why Rhythm Pharmaceuticals Stock Price is Rebounding

July 21, 2022 0

Rhythm Pharmaceuticals is Rebounding Rhythm Pharmaceuticals (RYTM) announced yesterday, July 20, 2022, that the French National …

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

July 20, 2022 0

Incyte Announces FDA Approval of Opzelura Cream for Vitiligo Incyte (INCY) announced today, July 19, 2022, …

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene Therapy Vectors for Ocular Diseases

July 20, 2022 0

Avista Therapeutics Avista Therapeutics’ mission is to develop innovative gene therapies for retinal diseases, including rare …

Shorting Biotech Firms with Solid Fundamentals

July 19, 2022 0

Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems …

Clene Inc: More Promising News for ALS Patients

July 14, 2022 0

The clinical-stage Clene Nanomedicine Firm Reported Significantly Decreased Mortality in Amyotrophic Lateral Sclerosis (ALS) CNM-Au8® treatment resulted …

CytomX Therapeutics Provided an Important Strategic Update

July 14, 2022 0

CytomX Therapeutics Update CytomX Therapeutics (CTMX) announced plans to focus on its emerging preclinical and early …

Vertex Pharmaceuticals to Acquire ViaCyte Inc to Accelerate its Potentially Curative VX-880 Programs in Type 1 Diabetes

July 12, 2022 0

Vertex Pharmaceuticals and ViaCyte Inc are in the NEWS Vertex Pharmaceuticals (VRTX) entered into a definitive …

Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

July 8, 2022 0

Is Merck to Acquire Seagen? The Wall Street Journal reported that Merck is in advanced talks …

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven Target Discovery Engine

July 7, 2022 0

Insilico Medicine Insilico Medicine is a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is …

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

July 6, 2022 0

Vertex Pharmaceuticals VX-880 for Type 1 Diabetes Vertex Pharmaceuticals (VRTX) announced that the FDA has lifted …

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

July 5, 2022 0

CureVac N.V. Files Lawsuit Against BioNTech for Infringement CureVac N.V. (CVAC), a company that develops therapeutics …

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

July 2, 2022 0

Celldex Therapeutics Interim Trial Data for Barzolvolimab Interim data from Celldex Therapeutics (CLDX) Phase 1b clinical …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals’ Product AMX0035 for ALS

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant Cancers

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn’s Disease

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Why Rhythm Pharmaceuticals Stock Price is Rebounding

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene Therapy Vectors for Ocular Diseases

Shorting Biotech Firms with Solid Fundamentals

Clene Inc: More Promising News for ALS Patients

CytomX Therapeutics Provided an Important Strategic Update

Vertex Pharmaceuticals to Acquire ViaCyte Inc to Accelerate its Potentially Curative VX-880 Programs in Type 1 Diabetes

Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven Target Discovery Engine

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines